摘要
表皮生长因子受体 (EGFR)在非小细胞肺癌 (NSCLC)患者中存在过表达。Cetuxumab(C2 2 5 ,erbitux)是一种单克隆抗体 ,可竞争性结合EGFR细胞外配体区 ,抑制肿瘤生长 ,与放化疗有协同作用。本文综述cetuxumab联合放化疗治疗晚期NSCLC的临床前和临床资料 ,显示出ce tuxumab具有良好耐受性。
The epidermal growth factor receptor(EGFR)is frequently overexpressed in non-small cell lung cancer(NSCLC).Cetuxumab(C225,Erbitux),a monoclonal antibody directed against ligand binding in the extracellular domain of EGFR,inhibits tumor growth and is synergistic with chemotherapy and radiation.This article reviews preclinical and clinical data supporting cetuxumab in combination with chemotherapy/radiation therapy for advanced NSCLC.Additional cetuxumab to chemotherapy is generally well tolerated.
出处
《癌症进展》
2005年第2期116-119,共4页
Oncology Progress
